Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Employees - 131900,
CEO - Mr. Joaquin Duato,
Sector - Healthcare,
Country - US,
Market Cap - 349.99B
Altman ZScore(max is 10): 4.06, Piotroski Score(max is 10): 6, Working Capital: $1490000000, Total Assets: $178287000000, Retained Earnings: $155179000000, EBIT: 22226000000, Total Liabilities: $108129000000, Revenue: $87696000000
AryaFin Target Price - $161.16 - Current Price $144.47 - Analyst Target Price $176.21
Ticker | JNJ |
Index | DJIA, S&P 500 |
Curent Price | 144.47 |
Change | 0.62% |
Market Cap | 349.99B |
Average Volume | 7.28M |
Income | 14.68B |
Sales | 87.69B |
Book Value/Share | 29.14 |
Cash/Share | 8.38 |
Dividend Est | 4.64 (3.21%) |
Dividend TTM | 4.91 (3.40%) |
Dividend Ex-Date | Nov 26, 2024 |
Employees | 131900 |
Moving Avg 20days | -3.48% |
Moving Avg 50days | -6.96% |
Moving Avg 200days | -6.74% |
Shares Outstanding | 2.41B |
Earnings Date | Oct 15 BMO |
Inst. Ownership | 72.73% |
Price/Earnings | 23.88 |
Forwad P/E | 13.66 |
PE Growth | 3.98 |
Price/Sales | 3.99 |
Price/Book | 4.96 |
Price/Cash | 17.24 |
Price/FCF | 16.87 |
Quick Ratio | 0.79 |
Current Ratio | 1.03 |
Debt/Equity | 0.51 |
Return on Assets | 8.58% |
Return on Equity | 20.89% |
Return on Investment | 14.47% |
Gross Margin | 68.67% |
Ops Margin | 24.60% |
Profit Margin | 16.75% |
RSI | 32.06 |
BETA(β) | 0.50 |
From 52week Low | 0.94% |
From 52week High | -14.44% |
EPS | 6.05 |
EPS next Year | 10.58 |
EPS next Qtr | 2.02 |
EPS this Year | 0.36% |
EPS next 5 Year | 6.00% |
EPS past 5 Year | -0.27% |
Sales past 5 Year | 1.31% |
EPS Y/Y | 15.10% |
Sales Y/Y | -8.03% |
EPS Q/Q | -43.91% |
Sales Q/Q | 5.27% |
Sales Surprise | 1.35% |
EPS Surprise | 9.68% |
ATR(14) | 2.35 |
Perf Week | -1.47% |
Perf Month | -5.64% |
Perf Quarter | -11.49% |
Perf Year | -5.74% |
Perf YTD | -7.83% |
Target Price | 176.21 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer